New Antimalarial Drug Development in India: Radical Curative Agents CIDRI 80/53 (Elubaquine) and WR 238605 (Tafenoquine)

dc.contributor.author	Dutta, G P
dc.contributor.author	Puri, S K
dc.date.accessioned	2009-09-08T09:02:16Z
dc.date.available	2009-09-08T09:02:16Z
dc.date.issued	2003
dc.identifier.citation	Proc Indian National Science Academy -2003-B69 No.6 871-882	en
dc.identifier.uri	http://hdl.handle.net/123456789/507
dc.description.abstract	Global efforts had been continued for the last 50) years, to find a safe radical curative (anti-relapse) drug to replace primaquine for the treatment of Plasomodium vivax and P. ovale, Throughout the world, more than 250 potential tissue. schizontocides had been synthesized and screened, and two new primaquine derivatives had been identified in primate malaria radical curative tests which could be the candidate drugs to replace primaquine:	en
dc.format.extent	6263850 bytes
dc.format.mimetype	application/pdf
dc.language.iso	en	en
dc.subject	Malaria	en
dc.subject	Anti-relapse drugs	en
dc.subject	CDRI 80/53/Bulaquine/Elubagttine	en
dc.subject	WR 238605/ Tafenoquine	en
dc.subject	Antimalarials	en
dc.subject	Plasmodium	en
dc.subject	Gametocytocide	en
dc.subject	Aablaquin	en
dc.title	New Antimalarial Drug Development in India: Radical Curative Agents CIDRI 80/53 (Elubaquine) and WR 238605 (Tafenoquine)	en
dc.type	Article	en